Issue Date: March 4, 2013
LEO Pharma, 4SC Ink Dermatology Deal
Leo Pharma, a Danish dermatology drug specialist, has signed a research and licensing agreement with Germany’s 4SC Discovery to research, develop, and commercialize an oral treatment for inflammatory skin disease. The partners say they are working on a compound in early-stage development that could significantly reduce symptoms of psoriasis. 4SC will receive $1.3 million in R&D financing and could get up to $125 million in milestone payments plus additional . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society